Before revision: Catalent inks deal to manufacture Sarepta's DMD gene therapy Medical uses Delandistrogene moxeparvovec is indicated for the treatment of ambulatory children aged four through five years of age with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene.
After revision: Medical uses Delandistrogene moxeparvovec is indicated for the treatment of ambulatory children aged four through five years of age with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene.